Streetbeat News

Analyst Ratings

AFL

B of A Securities analyst Joshua Shanker reinstates Aflac (NYSE:AFL) with a Buy rating and maintains a $77 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 1:15 pm

GTLB

RBC Capital analyst Matthew Hedberg reiterated an Outperform rating on GitLab (NASDAQ:GTLB) and maintained a $45 price target.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:15 pm

CASY

Benchmark analyst John Lawrence reiterated a Buy rating on Casey's General Stores (NASDAQ:CASY) and maintained a $275 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 1:13 pm

ONTO

Benchmark analyst Mark Miller maintains a Buy rating on Onto Innovation (NYSE:ONTO) and raises the price target from $97 to $118.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 1:10 pm

PLL

DA Davidson analyst Matt Summerville maintains a Buy rating on Piedmont Lithium (NASDAQ:PLL) and raises the price target from $90 to $96.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:09 pm

MED

MO

WBA

Wall Street's most accurate analysts recommend holding three defensive stocks with over 6% dividend yields: Altria Group (MO), Medifast (MED), and Walgreens Boots Alliance (WBA). These consumer staples sector stocks have high free cash flows and reward shareholders with high dividend payouts.

Portfolio Pulse from Lisa Levin

June 05, 2023 | 1:09 pm

CHPT

DA Davidson analyst Matt Summerville maintains a Buy rating on ChargePoint Holdings (NYSE:CHPT) but lowers the price target from $18 to $15.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:09 pm

F

Citigroup analyst Itay Michaeli upgrades Ford Motor (NYSE:F) from Neutral to Buy and raises the price target from $12.8 to $16.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:09 pm

COST

Oppenheimer analyst Rupesh Parikh maintains an Outperform rating on Costco Wholesale (NASDAQ:COST) and raises the price target from $550 to $575.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 1:05 pm

HOOK

Four analysts have provided ratings for HOOKIPA Pharma (NASDAQ:HOOK) within the last quarter, with three bullish and one indifferent. The average price target is $5.56, representing an upside from the current price of $1.13. The current average represents a 14.46% decrease from the previous average price target of $6.50.

Portfolio Pulse from Benzinga Insights

June 05, 2023 | 1:02 pm